A diagnostic host-specific transcriptome response for Mycoplasma pneumoniae pneumonia to guide pediatric patient treatment.
Viz-Lasheras S., Gómez-Carballa A., Bello X., Rivero-Calle I., Dacosta AI., Kaforou M., Habgood-Coote D., Cunnington AJ., Emonts M., Herberg JA., Wright VJ., Carrol ED., Paulus SC., Zenz W., Kohlfürst DS., Schweintzger N., Van der Flier M., de Groot R., Schlapbach LJ., Agyeman P., Pollard AJ., Fink C., Kuijpers TT., Anderson S., Von Both U., Pokorn M., Zavadska D., Tsolia M., Moll HA., Vermont C., Levin M., Martinón-Torres F., Salas A., EUCLIDS, PERFORM, and DIAMONDS consortia None.
Mycoplasma pneumoniae causes atypical pneumonia in children and young adults. Its lack of a cell wall makes it resistant to beta-lactams, which are the first-line treatment for typical pneumonia. Current diagnostic tests are time-consuming and have low specificity, leading clinicians to administer empirical antibiotics. Using a LASSO regression simulation approach and blood microarray data from 107 children with pneumonia (including 30 M. pneumoniae) we identify eight different transcriptomic signatures, ranging from 3-10 transcripts, that differentiate mycoplasma pneumonia from other bacterial/viral pneumonias with high accuracy (AUC: 0.84-0.95). Additionally, we demonstrate that existing signatures for broadly distinguishing viral/bacterial infections and viral/bacterial pneumonias are ineffective in distinguishing M. pneumoniae from viral pneumonia. The new signatures are successfully validated in an independent RNAseq cohort of children with pneumonia, demonstrating their robustness. The high sensibility of these signatures presents a valuable opportunity to guide the treatment and management of M. pneumoniae pneumonia patients.